24 SEP 2009 — Dr. Dan Rhodes introduces the next generation of Oncomine to the research community.

Oncomine Research Edition 4 represents substantial improvements to the Oncomine interface and the structure of the underlying data. Key improvements include a simplified interface, better searching and filtering, more consistent sample facts and analyses, and improved summarization. In addition, we’ve added data from more than 100 new cancer genomic studies!

Oncomine 4 Research Edition

30 JUL 2009 — Matt Anstett reviews the capabilities of the latest release of Oncomine. Oncomine 4.1 focuses on core capabilities that include gene summarization, concepts analysis, new Oncomine filters and security/administration improvements. These highly valuable additions will enable faster and more effective decisions in your oncology research.

Oncomine 4.1 - Features and Filters

19 MAY 2009 — We explore the possibility that a gene expression signature for angiogenesis can be used to identify cancer types and particular patients most likely to respond to angiogenesis inhibitors. We show that components of the angiogenesis pathway demonstrate correlated gene expression across tumors and that particular tumor types and patient sub-populations show variable activation of the angiogenesis gene expression signature. Notably, clear cell renal cell carcinomas show near universal over-expression of the signature, whereas other cancer types show over-expression in sub-populations of patients. In this webinar, we will discuss the approach, the angiogenesis signature genes, and the tumor populations that over-express these genes.

Angiogenesis webinar slides (PDF 1.97 MB)

We regret that there is no recording for this webinar.

27 MAR 2009 — After more than a year of work, we have released the all new Oncomine 4.0. In part one of this webinar, Matt Anstett walks through our motivation for redesigning Oncomine and reviews the major changes.
Open Flash Movie :: Part 1

In part two of this webinar, Dan Rhodes takes you throught the interface with examples based on common workflows.
Open Flash Movie :: Part 2

30 SEP 2008 — A recent study investigated the association of gene expression profiles with cetuximab response in metastatic colorectal cancer. The study identified a number of individual genes associated with response, including EGFR ligands amphiregulin and epiregulin.

In this webinar, we present an Oncomine™ analysis of the cetuximab response data, in which we utilized an unsupervised approach, Oncomine Clusters, to define the gene expression programs that differentiate subclasses of metastatic colorectal cancer, including those associated with response and lack of response to cetuximab therapy. Using the Oncomine Concepts Map, we were able to confirm the biological relevance of these gene expression programs and link the programs to underlying biology and other tumor types and subtypes, suggesting additional clinical populations that may benefit from cetuximab therapy.

Download slides (PDF 3.2 MB)
Open Flash Movie

25 JUN 2008 — Recently, Oncomine™ played a central role in the discovery and identification of SPINK1 as a key new therapeutic target and biomarker for prostate cancer (Cancer Cell, Volume 13 Issue 6: June 2008). Dr. Dan Rhodes and his colleagues at the University of Michigan expanded on the Cancer Outlier Profile Analysis (COPA) work they started with the ETS-family gene fusions in prostate cancer by performing a meta-analysis of the outlier results — Meta-COPA — to identify SPINK1 as their gene of interest.

In this webinar Dr. Rhodes uses the SPINK1 discovery as a case study to walk through the process used to identify the gene of interest through Meta-COPA analysis and then further verify the hypothesis with Oncomine. The COPA analysis is currently available in Oncomine v3.6. Meta-COPA is slated to be a standard feature in v4.0 to be released this fall.

Download slides (PDF 1.49 MB)
Open Flash Movie

28 MAY 2008 — Oncomine contains a wealth of gene expression data and analysis from tumors and cell lines. While gene expression analysis represents an important component of drug target discovery and validation, it alone may not be sufficient to identify optimal targets. In this webinar, Dr. Dan Rhodes presents Oncomine-based target discovery strategies that integrate gene expression data with additional genomics data types and resources including DNA copy number data and the COSMIC somatic mutation database. We will also explore analyses of gene expression data filtered by functional genomics shRNA data.

Download slides (PDF 1.41 MB)
Open Flash Movie

19 MAR 2008 — Pioneering work by Nevins and colleagues demonstrated that microarray-based pathway activation signatures can be used to predict pathway activity in human tumors and suggest strategies for tailoring targeted therapies. In this webinar, we utilize the Oncomine Concepts Map to analyze recently published pathway activation signatures for EGFR, ERBB2, B-Raf and Mek. We demonstrate that pathway activation signatures are associated with drug sensitivity as well as specific tumor sub-populations, suggesting new avenues for genomics-based drug development.

Download slides (PDF)
Download WMV (17.3 MB)
Download Paper (PDF)

28 JUN 2007
Download slides (PDF 2.64 MB)
Download WMV (22.3 MB)